Other reports have shown that increased expression of BNIP3 detected in hypoxic regions of lung and prostate cancers, glioblastoma multiforme, cervical tumors, endometrial cancer, breast carcinomas and gastric adenocarcinomas correlates with an aggressive tumor phenotype and a poor prognosis [58, 63–65]. Here, BNIP3 is linked to neoplasm.